Odraščal je blizu Bostona, hodil na Harvard in delal na MIT-ju.

Felix Wong, a 33-year-old biotech entrepreneur, has built his startup in Redwood City, California, despite spending much of his life in Massachusetts. Born in Quincy, Wong attended Braintree High School before earning two undergraduate degrees from Harvard University. He later pursued graduate studies and conducted postdoctoral research at the Massachusetts Institute of Technology (MIT). Despite these deep roots in the Bay State, Wong chose to establish his company in Silicon Valley, a decision that has sparked curiosity among colleagues and industry observers. The move came after years of academic and professional work in Boston. Wong's parents continue to reside in Massachusetts, maintaining ties to the region that shaped his early years. However, the allure of California’s innovation ecosystem and its robust venture capital scene ultimately influenced his decision. The biotechnology sector, long dominated by Boston-based firms, has seen increasing competition from San Francisco and other West Coast hubs. Wong’s startup, which focuses on gene-editing technologies, aims to leverage both cutting-edge research and the financial support available in California. In a recent interview, Wong described his choice as a strategic one. “California offers access to some of the brightest minds and the most flexible regulatory environment,” he said. “While Boston has been a leader in biotech, I wanted to build something that could scale quickly and reach global markets.” His team includes scientists and engineers who have previously worked at top institutions such as Stanford and UC Berkeley, further reinforcing the startup’s commitment to innovation. The timing of the startup’s launch coincides with growing interest in personalized medicine and synthetic biology. These fields require not only scientific expertise but also substantial investment, which many believe is more readily available in California. Wong’s company has already secured funding from several venture capital firms based in the state, including Sequoia Capital and Andreessen Horowitz. This financial backing has allowed the team to focus on developing prototypes and conducting clinical trials. Industry experts suggest that Wong’s decision reflects broader trends in the biotech landscape. While traditional centers like Boston remain influential, new players in California are challenging their dominance. “There’s a shift happening,” said Dr. Laura Chen, a professor at the University of California, San Francisco. “More researchers are choosing to start companies in California because of the infrastructure and talent pool available there.” Wong’s background underscores the personal and professional factors that often influence such decisions. Having lived in Cambridge for over a decade, he developed a strong network within academia and industry. Yet, the desire to break away from established norms and create something new led him to seek opportunities beyond the East Coast. “I wanted to be part of a movement that wasn’t just replicating what had already been done,” he explained. As the startup enters its second year of operations, it continues to attract attention from investors and collaborators. With plans to expand into Europe and Asia, Wong hopes to position his company as a leader in the next generation of biotechnology. For now, the sun-drenched streets of Redwood City serve as the backdrop for his ambitions.